ProBioGen: Selected partner
ProBioGen’s innovative technologies and expertise make it a key partner for advancing biopharmaceutical research and development. With a strong focus on cell line engineering, process development, and GMP manufacturing, ProBioGen supports a wide range of applications from vaccine production to therapeutic antibody development. Our collaboration with ProBioGen allows us to incorporate their GlymaxX® technology in our recombinant antibody expression services.
Key facts
- Specialization: Cell line engineering, process development, GMP manufacturing
- Technology: GlymaxX®, viral vector technologies, DirectedLuck® and more
- Services: Biopharmaceutical manufacturing, process development, cell-based assays, and others
- Website: www.probiogen.de
Location
Headquarters
Herbert-Bayer-Straße 8
13086 Berlin
Germany
About ProBiogen
ProBioGen is a renowned Contract Development and Manufacturing Organization (CDMO) based in Berlin, Germany. They specialize in fields like cell line engineering, process development, and GMP manufacturing.
ProBioGen’s proprietary GlymaxX® technology is designed to produce afucosylated antibodies, which demonstrate higher Antibody-Dependent Cellular Cytotoxicity (ADCC), leading to enhanced therapeutic efficacy against tumor cells and infections.
Our Workflow with ProBioGen
Screening & lead selection
- Phage Display screening
- Antibody engineering,
de-immunization, and humanization - Lead identification
Transient expression
- High-quality transient expression at evitria
- Purification by protein A/G/L and SEC
- Suitable for in vivo studies
- Option: afucosylation using GlymaxX® from ProBioGen
Characterization
- Bioconjugation
- Functional assays
- Developability assessments
- Cell line development and clinical/commercial manufacturing
CMC
- Stable cell line development
- Process Development
- GMP production for Phase I/II
Unlock the full potential of your research with ProBioGen and evitria
Through the strategic partnership with ProBioGen, evitria is equipped to offer superior afucosylated antibodies utilizing ProBioGen’s innovative GlymaxX® technology.
This partnership combines ProBioGen’s advanced afucosylation platform, which enhances antibody efficacy by boosting ADCC (Antibody-Dependent Cellular Cytotoxicity), with evitria’s expertise in CHO cell-based transient expression systems.
